<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03711578</url>
  </required_header>
  <id_info>
    <org_study_id>RP6530-1802</org_study_id>
    <nct_id>NCT03711578</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)</brief_title>
  <official_title>An Open Label, Phase II Study to Evaluate the Efficacy and Safety of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Adult Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhizen Pharmaceuticals SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhizen Pharmaceuticals SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the anti-tumor activity and safety of Tenalisib in patients with
      relapsed/refractory indolent Non-Hodgkin's Lymphoma (iNHL),
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 25, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 22, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>7 months</time_frame>
    <description>ORR is defined as sum of CR and PR rates and will be assessed according to the Lugano Classification for initial evaluation, staging, and response assessment of Non-Hodgkin lymphoma. (Cheson-2014)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>7 months</time_frame>
    <description>CR rate will be assessed according to the Lugano Classification for initial evaluation, staging, and response assessment of non-Hodgkin lymphoma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>7 months</time_frame>
    <description>PFS is defined as the time of the first dose of Tenalisib to disease progression or death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>7 months</time_frame>
    <description>DoR is measured from the initial response to disease progression or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>7 months</time_frame>
    <description>Safety and tolerability of Tenalisib</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Tenalisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Tenalisib 800 mg BID in 28-Days Cycle for 8 Cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenalisib,</intervention_name>
    <description>BID, Orally</description>
    <arm_group_label>Tenalisib</arm_group_label>
    <other_name>RP6530</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically confirmed diagnosis of indolent B-cell NHL, with
             histological subtype limited to:

               1. Follicular lymphoma (FL) G1, G2, or G3a

               2. Marginal zone lymphoma (MZL) (splenic, nodal, or extra-nodal)

               3. Lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM)

               4. Small lymphocytic lymphoma (SLL) with absolute lymphocyte count &lt;5 x10^9/L at the
                  time of diagnosis and at study entry.

          2. Relapsed or refractory after ≥ 2 prior lines of therapy (refractory defined as not
             responding to a standard regimen or progressing within 6 months of the last course of
             a standard regimen). Patients must have received rituximab and alkylating agents.

          3. Patients must have at least one bi-dimensionally measurable lesion (that has not been
             previously irradiated) with the longest diameter ≥ 1.5 cm.

          4. Male or female patients &gt; 18 years of age.

          5. ECOG performance status ≤ 2.

          6. Life expectancy of at least 3 months.

          7. Adequate bone marrow, liver, and renal function as assessed by the following
             laboratory requirements conducted within 7 days before starting study treatment:

               1. Hemoglobin ≥ 9 g/dl

               2. Absolute neutrophil count (ANC) ≥ 1 x 10^9/L

               3. Platelets ≥50 x 10^9/L (patient without BM involvement) and 30 x 10^9/L (patient
                  with BM involvement)

               4. Total bilirubin ≤1.5 times the upper limit of normal (ULN)

               5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x ULN if
                  known liver involvement

               6. Creatinine ≤ 1.5 mg/dL OR calculated creatinine clearance ≥ 50 mL/min (as
                  calculated by the Cockcroft-Gault method)

          8. Use of an effective means of contraception for female patients of child-bearing
             potential, and all male partners.

          9. Willingness and ability to comply with trial and follow-up procedures, give written
             informed consent.

        Exclusion Criteria:

          1. FL grade 3b or transformed disease or CLL

          2. Cancer therapy within 3 weeks (21 days) or 5 half-lives (whichever is shorter) prior
             to C1D1. Corticosteroids (prednisone or equivalent) at a dose of &lt; 20 mg daily are
             allowed. Corticosteroid should be stabilized for at least 1 week prior to C1D1

          3. Auto-SCT within 3 months from C1D1 (patients must not have active graft versus- host
             disease)

          4. History of having received an Allo-SCT

          5. Active hepatitis B or C infection

          6. Known history of human immunodeficiency virus (HIV) infection

          7. Evidence of ongoing severe systemic bacterial, fungal or viral infection

          8. Known primary central nervous system lymphoma or any preexisting neurologic
             manifestations

          9. Known history of drug-induced liver injury, alcoholic liver disease, primary biliary
             cirrhosis, ongoing extrahepatic obstruction caused by stones, cirrhosis of the liver
             or portal hypertension;

         10. Prior exposure to drug that specifically inhibits PI3K

         11. Pregnancy or lactation

         12. Myeloid growth factors or red blood cells/ platelet transfusion within 14 days prior
             to C1D1

         13. Drug administration within 1 week prior to C1D1

               1. Strong inhibitors or inducers of CYP3A4, CYP2C9, including grapefruit products,
                  herbal supplements and drugs

               2. Substrates of CYP3A4 enzyme with a narrow therapeutic range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clearview Cancer Institute</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida cancer specialists &amp; Research Institute</name>
      <address>
        <city>Florida City</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist/ South</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists/North</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCA Midwest Health Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blacktown Hospital, Blacktown Cancer and Haematology Center</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brisbane Clinic for Lymphoma, Myeloma and Leukaemia,</name>
      <address>
        <city>Greenslopes,</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Flynn Private Hospital,</name>
      <address>
        <city>Tugun</city>
        <state>Queensland</state>
        <zip>4224</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Hodgkin lymphoma,</keyword>
  <keyword>Tenalisib</keyword>
  <keyword>RP6530</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

